Targeting the N protein-dependent LINC01002-miR-4324-FRMD8 axis may provide a novel therapeutic idea for early intervention in the IFN-dominated immune evasion induced by SARS-CoV-2, thereby ameliorating the severe inflammatory response caused by COVID-19. This evidence concerns the gene IFNA1 and COVID-19.